Paris, France, May 13, 2015 – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces its revenue for the first quarter of 2015.
Income statement
Activity
The revenue recorded by NANOBIOTIX during the first quarter of 2015 corresponds to the upfront payment (pro-rata share) received by the company from Taiwan-based PharmaEngine, within the framework of the licensing contract signed in August 2012 for the development and commercialization of the lead product, NBTXR3 in the Asia-Pacific region. The upfront payment totaled €810,640, generating revenue of €46,031 over the period based on a straight-line method of apportioning the revenue across the period between the date the contract was signed and the scheduled marketing launch in the region. The invoicing of services totaled €960 for the first quarter of 2015. In total, revenue for the first quarter amounted to €46,991 which is fully in line with company expectations.
During the first quarter, the Company announced that Professor Robert Langer, Institute Professor at the Massachusetts Institute of Technology (MIT), became a Scientific Advisor to Nanobiotix. Professor Langer presides over the largest academic biomedical engineering laboratory in the world. With a CE mark anticipated in 2016, the Company has been preparing to scale-up production further to meet the needs of future commercialization. In addition, Nanobiotix is anticipating an increase in demand for product for clinical trials in the coming years in Europe and in the United States. Therefore, in March 2015, Nanobiotix appointed CordenPharma as its manufacturing partner. The new manufacturing line will increase the amount of NBTXR3 product available for both commercialisation and trial purposes.
Moreover, in January, the Company announced the transfer of its shares from compartment C to compartment B of the regulated market of Euronext in Paris thanks to its stock market capitalization increase performances during 2014.
- ENDS -
Next financial press release: revenue for the second quarter of 2015, on July 15, 2015
Notes To Editors
About NANOBIOTIX: www.nanobiotix.com/fr
Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The company’s first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy with a view to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy treatments and are meant to treat potentially a wide variety of cancers including Soft Tissue Sarcoma, Head and Neck Cancer, Liver Cancers, Prostate Cancer, Breast Cancer, Glioblastoma, etc., via multiple routes of administration.
Nanobiotix’s lead product NBTXR3, based on NanoXray, is currently under clinical development for Soft Tissue Sarcoma and locally advanced Head and Neck Cancer. The company has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia.
Nanobiotix is listed on the regulated market of Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP). The company, based in Paris, France, opened an affiliate office in the Boston area of the US in September 2014.
Issued for and on behalf of Nanobiotix by Instinctif Partners.
For more information please contact:
Nanobiotix
Sarah Gaubert
Head of Communication and Public Affairs
+33 (0)1 40 26 07 55
contact@nanobiotix.com
Media relations
France - NewCap
Annie-Florence Loyer
+33 (0)6 88 20 35 59
afloyer@newcap.fr
Outside France - Instinctif Partners
Melanie Toyne Sewell / Jayne Crook
+44 (0) 207 457 2020
nanobiotix@instinctif.com
Help employers find you! Check out all the jobs and post your resume.
Income statement
| In € | Q1 2014 |
Q1 2013 |
||||||
| Revenues | 46,991 | 45,343 | ||||||
| Of which : | ||||||||
|
License |
46,031 | 45,343 | ||||||
|
Services |
960 | - | ||||||
Activity
The revenue recorded by NANOBIOTIX during the first quarter of 2015 corresponds to the upfront payment (pro-rata share) received by the company from Taiwan-based PharmaEngine, within the framework of the licensing contract signed in August 2012 for the development and commercialization of the lead product, NBTXR3 in the Asia-Pacific region. The upfront payment totaled €810,640, generating revenue of €46,031 over the period based on a straight-line method of apportioning the revenue across the period between the date the contract was signed and the scheduled marketing launch in the region. The invoicing of services totaled €960 for the first quarter of 2015. In total, revenue for the first quarter amounted to €46,991 which is fully in line with company expectations.
During the first quarter, the Company announced that Professor Robert Langer, Institute Professor at the Massachusetts Institute of Technology (MIT), became a Scientific Advisor to Nanobiotix. Professor Langer presides over the largest academic biomedical engineering laboratory in the world. With a CE mark anticipated in 2016, the Company has been preparing to scale-up production further to meet the needs of future commercialization. In addition, Nanobiotix is anticipating an increase in demand for product for clinical trials in the coming years in Europe and in the United States. Therefore, in March 2015, Nanobiotix appointed CordenPharma as its manufacturing partner. The new manufacturing line will increase the amount of NBTXR3 product available for both commercialisation and trial purposes.
Moreover, in January, the Company announced the transfer of its shares from compartment C to compartment B of the regulated market of Euronext in Paris thanks to its stock market capitalization increase performances during 2014.
- ENDS -
Next financial press release: revenue for the second quarter of 2015, on July 15, 2015
Notes To Editors
About NANOBIOTIX: www.nanobiotix.com/fr
Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The company’s first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy with a view to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy treatments and are meant to treat potentially a wide variety of cancers including Soft Tissue Sarcoma, Head and Neck Cancer, Liver Cancers, Prostate Cancer, Breast Cancer, Glioblastoma, etc., via multiple routes of administration.
Nanobiotix’s lead product NBTXR3, based on NanoXray, is currently under clinical development for Soft Tissue Sarcoma and locally advanced Head and Neck Cancer. The company has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia.
Nanobiotix is listed on the regulated market of Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP). The company, based in Paris, France, opened an affiliate office in the Boston area of the US in September 2014.
Issued for and on behalf of Nanobiotix by Instinctif Partners.
For more information please contact:
Nanobiotix
Sarah Gaubert
Head of Communication and Public Affairs
+33 (0)1 40 26 07 55
contact@nanobiotix.com
Media relations
France - NewCap
Annie-Florence Loyer
+33 (0)6 88 20 35 59
afloyer@newcap.fr
Outside France - Instinctif Partners
Melanie Toyne Sewell / Jayne Crook
+44 (0) 207 457 2020
nanobiotix@instinctif.com
Help employers find you! Check out all the jobs and post your resume.
